{"schemaVersion":"cwiki-fiche-1.0","identifiers":{"inchiKey":"IVLWWVXVWRIXSS-UHFFFAOYSA-N","prefName":"JWH-072","symbol":"JWH-072","iupacName":"naphthalen-1-yl-(1-propylindol-3-yl)methanone","aliases":["JWH-072","1-propyl-3-(1-naphthoyl)indole","naphthalen-1-yl(1-propyl-1H-indol-3-yl)methanone"],"cas":null,"pubchemCid":"45271208","chebiId":null,"smiles":"CCCN1C=C(C2=CC=CC=C21)C(=O)C3=CC=CC4=CC=CC=C43","molecularFormula":"C22H19NO","molecularWeight":313.4,"xrefs":{"pubchem":"https://pubchem.ncbi.nlm.nih.gov/compound/45271208"}},"classification":{"family":"scra","familyLabel":"Synthetic cannabinoid (SCRA)","origin":"synthetic","originLabel":"Synthétique","structuralClassFr":null},"originSynthesis":{"heading":"Origin (pharmaceutical research → illicit market)","summaryFr":"No biosynthetic pathway: this is a synthetic compound, obtained by acylation at position 3 of an N-alkylated indole. Only the class of synthesis is described here.","originNote":"Entirely synthetic compound: no natural occurrence is recorded for this molecule, and it is not reported in cannabis. The oldest human report found in the sources consulted is a 2012 clinical case in which it was identified in the serum, urine and cerebrospinal fluid of a patient, alongside other substances (Thornton et al., 2012). Those authors state that it had not previously been reported in the literature.","discovered":""},"pharmacology":{"summaryFr":"JWH-072 belongs to the 1-alkyl-3-(1-naphthoyl)indole series, which came out of the work of John W. Huffman's team at Clemson University. In vitro, its affinity is about 170 nM for CB2 and 1 052 nM for CB1, with a preference for CB2; no functional measurement was found in the sources consulted. In humans, the data are limited to a 2012 clinical case reporting its presence in several biological fluids, without establishing its own role.","receptorSummaryFr":"JWH-072 binds both cannabinoid receptors, with a higher affinity for CB2 than for CB1. The reported Ki values are 170 nM at the human CB2 receptor and 1 052 nM at the CB1 receptor from rat brain, as reported in De Freitas et al. (2009) and carried into ChEMBL. Thornton et al. (2012) describe it as a CB2 agonist, with no functional measurement found in the sources consulted. In the halogenated-naphthoyl series studied by Wiley et al. (2012), N-propyl derivatives are reported as more CB2-selective than their N-pentyl analogues. No G-protein activation data were found for this molecule in the sources consulted.","binding":[{"target":"CB2","efficacy":"full_agonist","relativeActivity":60,"reported":"Ki 170 nM (De Freitas et coll., 2009, valeur rapportée dans ChEMBL ; récepteur CB2 humain). Agoniste selon Thornton et coll., 2012 ; efficacité fonctionnelle non trouvée dans les sources consultées","confidence":"medium"},{"target":"CB1","efficacy":"modulator","relativeActivity":40,"reported":"Ki 1 052 nM (De Freitas et coll., 2009, valeur rapportée dans ChEMBL ; récepteur CB1 de cerveau de rat). Efficacité fonctionnelle non trouvée dans les sources consultées","confidence":"medium"}],"references":[{"label":"Huffman et coll., relations structure-activité des 1-alkyl-3-(1-naphtoyl)indoles aux récepteurs CB1 et CB2, Bioorg Med Chem 2005","pmid":"15582455","doi":"10.1016/j.bmc.2004.09.050","url":"https://pubmed.ncbi.nlm.nih.gov/15582455/"},{"label":"Wiley et coll., synthèse et pharmacologie des 1-alkyl-3-(1-naphtoyl)indoles à naphtoyle halogéné, Bioorg Med Chem 2012","pmid":"22341572","doi":"10.1016/j.bmc.2012.01.038","url":"https://pubmed.ncbi.nlm.nih.gov/22341572/"},{"label":"Thornton et coll., détection simultanée de plusieurs drogues de synthèse chez un patient présentant une psychose prolongée, Clin Toxicol 2012","pmid":"23163617","doi":"10.3109/15563650.2012.744996","url":"https://pubmed.ncbi.nlm.nih.gov/23163617/"},{"label":"De Freitas et coll., modèles CoMFA et CoMSIA des ligands indoliques des récepteurs CB1 et CB2, Eur J Med Chem 2009","pmid":"19249138","doi":"10.1016/j.ejmech.2009.01.026","url":"https://pubmed.ncbi.nlm.nih.gov/19249138/"},{"label":"ChEMBL, fiche composé CHEMBL563390 (JWH-072), valeurs Ki issues du document CHEMBL1158401","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL563390/"},{"label":"PubChem, Compound Summary CID 45271208, JWH-072","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/45271208"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026, bloc des familles indol-3-yl méthanone","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"Arrêté du 14 octobre 2019 modifiant l'arrêté du 22 février 1990, Légifrance","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000039223507"},{"label":"Organe international de contrôle des stupéfiants, Liste verte 2026 (conventions de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}]},"pharmacokinetics":null,"metabolism":null,"detection":null,"subjectiveEffects":{"profile":[{"key":"calm","label":"Calm","description":"Relaxation of body and mind; reduced mental noise without marked drowsiness.","intensity":8},{"key":"focus","label":"Clarity","description":"Sustained attention and clear thinking; functional lucidity, not euphoria.","intensity":4},{"key":"sleep","label":"Sleep","description":"Sedative effect: aids sleep onset and the continuity of deep sleep.","intensity":6},{"key":"appetite","label":"Appetite","description":"Stimulation of hunger and of taste appreciation (the “munchies” effect).","intensity":6},{"key":"uplift","label":"High","description":"Euphoria and sensory intensity; altered perception of time and space.","intensity":6}],"doseRanges":null,"humanDataCharacterised":false},"indications":{"approvedMedicines":[]},"harmProfile":{"unstudiedBanner":true,"bannerTextFr":"Aucune dose humaine caractérisée : données animales / in vitro uniquement. Profil d'effet, marge de sécurité et toxicité aiguë non documentés en clinique humaine.","toxicologyFr":null},"legal":{"scheduleStatus":"unscheduled","scheduleLabel":"Unscheduled","frScheduleStatus":"controlled-clause","tiers":[{"jurisdiction":"international","jurisdictionLabel":"International","label":null,"reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"eu","jurisdictionLabel":"Union européenne","label":"At EU level, no harmonised control measure is documented for this molecule in the sources consulted: control falls under national legislation. At international level, it is not named in the 2026 Green List of the International Narcotics Control Board, which lists substances under the 1971 Conventions.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null},{"jurisdiction":"fr","jurisdictionLabel":"France","label":"JWH-072 is not named in the consolidated list of substances classed as narcotics, updated on 16 February 2026. It does, however, fall under the generic definition of indol-3-yl methanones: the indole nitrogen carries an alkyl substituent (here a propyl group), and the methanone bridge carbon carries a naphthyl group (here 1-naphthyl). Its structure meets both conditions, which places it under the family-clause regime. The right-hand column of this block of the list refers to the decree of 14 October 2019 amending the decree of 22 February 1990.","reference":null,"url":null,"effectiveDate":null,"lastVerified":"2026-05-01","supersededBy":null}],"sourcesFr":"EUR-Lex, UNODC, CND, ANSM, IUPHAR/BPS, ChEBI, EUDA."},"references":[{"label":"Huffman et coll., relations structure-activité des 1-alkyl-3-(1-naphtoyl)indoles aux récepteurs CB1 et CB2, Bioorg Med Chem 2005","pmid":"15582455","doi":"10.1016/j.bmc.2004.09.050","url":"https://pubmed.ncbi.nlm.nih.gov/15582455/"},{"label":"Wiley et coll., synthèse et pharmacologie des 1-alkyl-3-(1-naphtoyl)indoles à naphtoyle halogéné, Bioorg Med Chem 2012","pmid":"22341572","doi":"10.1016/j.bmc.2012.01.038","url":"https://pubmed.ncbi.nlm.nih.gov/22341572/"},{"label":"Thornton et coll., détection simultanée de plusieurs drogues de synthèse chez un patient présentant une psychose prolongée, Clin Toxicol 2012","pmid":"23163617","doi":"10.3109/15563650.2012.744996","url":"https://pubmed.ncbi.nlm.nih.gov/23163617/"},{"label":"De Freitas et coll., modèles CoMFA et CoMSIA des ligands indoliques des récepteurs CB1 et CB2, Eur J Med Chem 2009","pmid":"19249138","doi":"10.1016/j.ejmech.2009.01.026","url":"https://pubmed.ncbi.nlm.nih.gov/19249138/"},{"label":"ChEMBL, fiche composé CHEMBL563390 (JWH-072), valeurs Ki issues du document CHEMBL1158401","pmid":null,"doi":null,"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL563390/"},{"label":"PubChem, Compound Summary CID 45271208, JWH-072","pmid":null,"doi":null,"url":"https://pubchem.ncbi.nlm.nih.gov/compound/45271208"},{"label":"ANSM, Liste consolidée des substances classées comme stupéfiants, mise à jour du 16 février 2026, bloc des familles indol-3-yl méthanone","pmid":null,"doi":null,"url":"https://ansm.sante.fr/uploads/2026/02/17/20260217-stupefiants-liste-consolidee.pdf"},{"label":"Arrêté du 14 octobre 2019 modifiant l'arrêté du 22 février 1990, Légifrance","pmid":null,"doi":null,"url":"https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000039223507"},{"label":"Organe international de contrôle des stupéfiants, Liste verte 2026 (conventions de 1971)","pmid":null,"doi":null,"url":"https://www.incb.org/incb/uploads/documents/Psychotropics/forms/greenlist/2026/2510307E.pdf"}],"meta":{"slug":"jwh-072","url":"https://en.phytogrammes.com/wiki/jwh-072","lastVerified":"2026-05-01","dataUpdatedAt":"2026-10-13","confidence":"high","dataCompletenessPct":90,"disclaimerFr":"Contenu éditorial informatif, sans valeur d'avis médical ni juridique. Sources primaires citées par fiche. Réservé aux adultes."}}